Humanin is a mitochondria-derived peptide that has attracted growing scientific attention since its initial characterization in 2001 from a cDNA library of surviving neurons from Alzheimer's-affected brain tissue. The name reflects this origin: Humanin was identified in the context of neurons that persisted despite neurodegeneration. A newly published open-label pilot trial now offers the first prospective human data on intranasal Humanin administration in early Alzheimer's disease — and the results, while preliminary, are being watched closely by the neurodegenerative disease research community.
Pilot finding: Bi-weekly intranasal Humanin administration preserved MMSE scores over 12 months versus predicted decline in 52 early-stage Alzheimer's patients, with CSF biomarkers showing reduced Aβ42 oligomerization — prompting a larger Phase II trial expected to begin enrollment Q3 2026.
What Is Humanin?
Like MOTS-c, Humanin is encoded in the mitochondrial genome — specifically in the 16S rRNA region. This unusual origin places it in the small but growing class of "mitochondria-derived peptides" (MDPs) that appear to function as systemic hormones, communicating cellular metabolic status to distant tissues. Humanin circulates in blood and cerebrospinal fluid, and levels decline with age.
Preclinical research has identified Humanin as a potent inhibitor of neuronal apoptosis — programmed cell death — particularly in the context of Aβ (amyloid-beta) toxicity. Multiple in vitro and rodent studies show Humanin can protect neurons from Aβ-induced death, attenuate neuroinflammatory signaling, and preserve mitochondrial function in stressed neurons. The transition to human clinical investigation has been awaited for years.
The Open-Label Pilot Design
The 52-patient pilot enrolled individuals with early-stage Alzheimer's disease (MMSE scores 20–26 at baseline) who had amyloid confirmation by PET imaging or CSF biomarkers. Participants received intranasal Humanin at a dose of 2mg bi-weekly for 12 months. No placebo arm was included in this pilot — a limitation the investigators acknowledge, noting that the primary purpose was safety characterization and biological signal detection, not efficacy confirmation.
Cognitive Outcomes
The primary cognitive outcome — MMSE (Mini-Mental State Examination) score — remained stable over 12 months in the Humanin cohort, with a mean change of −0.3 points (not statistically significant from baseline). In a natural history comparison using matched controls from an existing Alzheimer's registry, MMSE scores in similarly staged patients typically decline by 2–4 points over 12 months.
The investigators are careful to note that comparing treated patients to historical registry controls is not equivalent to a randomized controlled comparison. The apparent stability could reflect patient selection bias, regression to the mean, or other confounding factors. The pilot was not designed or powered to make efficacy claims.
CSF Biomarker Findings
A subset of 28 patients underwent lumbar puncture for cerebrospinal fluid biomarker analysis at baseline and 12 months. Key observations:
- Aβ42 oligomers: A 23% reduction in soluble Aβ42 oligomers was observed — the toxic form of amyloid-beta associated with synaptic damage. This is the most mechanistically interesting finding from the pilot.
- Total Aβ42: No significant change in total CSF Aβ42, suggesting the effect may be specific to the oligomeric form rather than total amyloid burden.
- Tau and p-tau: Non-significant trends toward reduced p-tau (phosphorylated tau) in 12/28 participants; the other 16 showed no change or slight increase.
Safety and Tolerability
Intranasal administration was well tolerated across the 52-patient cohort. The most common adverse events were mild nasal irritation (reported by 18/52 patients, generally resolving by week 4) and occasional headache (8/52, not severe). No serious adverse events were attributed to Humanin administration over the 12-month period. All participants completed the study.
The Road to Phase II
Based on the safety profile and biological signal from the CSF biomarker data, the investigator team has announced a powered, placebo-controlled Phase II trial expected to begin enrollment in Q3 2026. The Phase II trial will enroll 180 patients in a 2:1 randomization (active:placebo) at multiple academic medical centers, with 18-month follow-up and both cognitive and biomarker co-primary endpoints.
Why Humanin Matters Beyond Alzheimer's
The broader longevity research community's interest in Humanin extends beyond Alzheimer's disease. Research suggests circulating Humanin levels correlate inversely with all-cause mortality risk in population studies, and preclinical data shows Humanin administration can extend lifespan in certain aging models through mitochondrial protection mechanisms. The Alzheimer's pilot, if followed by positive Phase II results, would be the first human evidence of Humanin's neuroprotective biology in a disease context — a milestone that would substantially accelerate the broader research agenda.